Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiopoietin-like protein 7 (ANGPTL7)
- Target
- ANGPTL7
- Molecular classification
- Secreted glycoprotein, Angiopoietin-like protein family, Orphan ligand (no confirmed receptor), Not a receptor, enzyme, channel, or transporter
01
Overview
Angiopoietin-like 7 is a secreted protein within the angiopoietin-like family. It contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain, is expressed in the cornea, trabecular meshwork, and is elevated in glaucoma. ANGPTL7 can inhibit angiogenesis in the cornea, maintaining its avascularity, but may stimulate angiogenesis under other pathological conditions such as cancer. It regulates extracellular matrix protein deposition and is upregulated by corticosteroids and TGF-β in ocular tissues. Its functions in other organs and its role as a therapeutic target or biomarker are actively being investigated, but it currently has no confirmed direct drug interactions or receptor partners.
- Other names
- Corneal-derived transcript 6 (CDT6)angiopoietin-related protein 7
02
Mechanism of action
For corticosteroids and TGF-β, mechanism involves upregulation of ANGPTL7, which stabilizes corneal avascularity and modifies extracellular matrix in trabecular meshwork cells
03
Biological functions
Regulation of extracellular matrix composition (collagen and proteoglycans)Maintenance of corneal avascularity and transparencyRegulation of angiogenesis, with context-dependent anti-angiogenic or pro-angiogenic effectsPossible roles in lipid and glucose metabolism, inflammation, and hematopoiesis (general functions of ANGPTL family)
04
Disease associations
Glaucoma: elevated ANGPTL7 in aqueous humor; influences trabecular meshwork and intraocular pressureCancer: upregulated in several cancers, especially under hypoxic conditions; may affect tumor angiogenesisCorneal diseases (e.g., keratoconus)Potential role in inflammatory and metabolic disorders (general to ANGPTL family)
05
Safety considerations
Therapeutic modulation may risk abnormal angiogenesis or extracellular matrix remodeling, which could affect ocular pressure or tumor vasculatureLack of identified receptor makes direct targeting challenging
06
Interacting drugs
None specifically established in the literature as of September 2025 (Corticosteroids upregulate ANGPTL7 expression)
07
Biomarkers
ANGPTL7 protein levels in aqueous humor as a potential biomarker for glaucomaPossibly in cancer diagnostics as a circulating factor
Beyond the preview
Go deeper on Angiopoietin-like protein 7 (ANGPTL7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiopoietin-like protein 7 (ANGPTL7).